Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CAL-130 Hydrochloride is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 1,300 | 5日内发货 | ||
5 mg | ¥ 2,190 | 5日内发货 | ||
25 mg | ¥ 5,940 | 6-8周 | ||
50 mg | ¥ 7,720 | 6-8周 | ||
100 mg | ¥ 11,900 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,250 | 5日内发货 |
产品描述 | CAL-130 Hydrochloride is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM). |
靶点活性 | p110α:115 nM, p110γ:6.1 nM, p110δ:1.3 nM, p110β:56 nM |
体外活性 | CAL-130 preferentially inhibits the function of both p110γ and p110δ catalytic domains (IC50s: 1.3 and 6.1 nM for p110δ and p110γ, 115 and 56 nM for p110α and p110β). CAL-130 does not inhibit additional intracellular signaling pathways (i.e., p38 MAPK or insulin receptor tyrosine kinase) that are critical for general cell function and survival. |
体内活性 | The clinical significance of interfering with the combined activities of PI3Kγ and PI3Kδ is determined by administering CAL-130 to Lck/Ptenfl/fl mice with established T cell acute lymphoblastic leukemia. Candidate animals for survival studies are ill-appearing, have a white blood cell count above 45,000/μL, evidence of blasts on peripheral smear, and a majority of circulation cells (>75%) staining double-positive for Thy1.2 and Ki-67. Mice receive an oral dose (10 mg/kg) of CAL-130 every 8 hr for a period of 7 days and are then followed until moribund. Despite the limited duration of therapy, CAL-130 is highly effective in extending the median survival for treated animals to 45 days as compared to 7.5 days for the control group. |
分子量 | 462.94 |
分子式 | C23H23ClN8O |
CAS No. | 1431697-78-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (108.01 mM), sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1601 mL | 10.8005 mL | 21.6011 mL | 54.0027 mL |
5 mM | 0.432 mL | 2.1601 mL | 4.3202 mL | 10.8005 mL | |
10 mM | 0.216 mL | 1.0801 mL | 2.1601 mL | 5.4003 mL | |
20 mM | 0.108 mL | 0.54 mL | 1.0801 mL | 2.7001 mL | |
50 mM | 0.0432 mL | 0.216 mL | 0.432 mL | 1.0801 mL | |
100 mM | 0.0216 mL | 0.108 mL | 0.216 mL | 0.54 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CAL-130 Hydrochloride 1431697-78-7 PI3K/Akt/mTOR signaling PI3K CAL 130 Hydrochloride CAL130 Hydrochloride Inhibitor inhibitor inhibit